Drug Development Watch: Attovia Therapeutics says ATTO-1310 showed preliminary proof-of-concept in chronic pruritus and high-itch atopic dermatitis, with Phase 2 plans for 2027 and an IPO cash boost extending its runway. Clinical Evidence in Focus: A Chinese real-world study reports that adding adjuvant immunotherapy after surgery didn’t significantly improve outcomes for resectable NSCLC patients who already achieved pathological complete response. Ophthalmology Update: Roche’s Vabysmo (faricimab) improved vision and retinal health in a China/Hong Kong-led SALWEEN study for polypoidal choroidal vasculopathy, with many patients showing no retinal fluid at 2 years. Hospital Care Innovation: Guangzhou is expanding “tubeless” thoracic surgery across more hospitals, aiming for faster recovery with fewer tubes and earlier mobilization. Tech for Health: Westlake University says China’s first AI-assisted “Class 1” innovative drug got NMPA approval for mild-to-moderate COVID-19. Research Openness: The Chinese Academy of Sciences’ automation institute launched a new international open-access journal to share scientific data globally. Public Health & Safety: Microsoft warns of Chinese-linked spoofed download sites delivering backdoors targeting major tech brands, including healthcare-adjacent organizations. Disaster Response (Health Angle): On the China-Nepal border mudslide, China reports 21 dead and 541 missing, while India continues sending medical supplies and rescue teams.